In:
PLOS ONE, Public Library of Science (PLoS), Vol. 16, No. 4 ( 2021-4-7), p. e0248097-
Kurzfassung:
Although combination BRAF and MEK inhibitors are highly effective for the 40–50% of cutaneous metastatic melanomas harboring BRAF V600 mutations, targeted agents have been ineffective for BRAF V600 wild-type (wt) metastatic melanomas. The SU2C Genomics-Enabled Medicine for Melanoma Trial utilized a Simon two-stage optimal design to assess whether comprehensive genomic profiling improves selection of molecular-based therapies for BRAF V600 wt metastatic melanoma patients who had progressed on standard-of-care therapy, which may include immunotherapy. Of the response-evaluable patients, binimetinib was selected for 20 patients randomized to the genomics-enabled arm, and nine were treated on the alternate treatment arm. Response rates for 27 patients treated with targeted recommendations included one (4%) partial response, 18 (67%) with stable disease, and eight (30%) with progressive disease. Post-trial genomic and protein pathway activation mapping identified additional drug classes that may be considered for future studies. Our results highlight the complexity and heterogeneity of metastatic melanomas, as well as how the lack of response in this trial may be associated with limitations including monotherapy drug selection and the dearth of available single and combination molecularly-driven therapies to treat BRAF V600 wt metastatic melanomas.
Materialart:
Online-Ressource
ISSN:
1932-6203
DOI:
10.1371/journal.pone.0248097
DOI:
10.1371/journal.pone.0248097.g001
DOI:
10.1371/journal.pone.0248097.g002
DOI:
10.1371/journal.pone.0248097.g003
DOI:
10.1371/journal.pone.0248097.t001
DOI:
10.1371/journal.pone.0248097.t002
DOI:
10.1371/journal.pone.0248097.s001
DOI:
10.1371/journal.pone.0248097.s002
DOI:
10.1371/journal.pone.0248097.s003
DOI:
10.1371/journal.pone.0248097.s004
DOI:
10.1371/journal.pone.0248097.s005
DOI:
10.1371/journal.pone.0248097.s006
DOI:
10.1371/journal.pone.0248097.s007
DOI:
10.1371/journal.pone.0248097.s008
DOI:
10.1371/journal.pone.0248097.s009
DOI:
10.1371/journal.pone.0248097.s010
DOI:
10.1371/journal.pone.0248097.s011
DOI:
10.1371/journal.pone.0248097.s012
DOI:
10.1371/journal.pone.0248097.s013
DOI:
10.1371/journal.pone.0248097.s014
DOI:
10.1371/journal.pone.0248097.s015
DOI:
10.1371/journal.pone.0248097.s016
Sprache:
Englisch
Verlag:
Public Library of Science (PLoS)
Publikationsdatum:
2021
ZDB Id:
2267670-3
Bookmarklink